ISPOR - HPR1 Evaluating High-Cost Innovative Medicines: A Three-Year Analysis of Pricing Trends in France's Early Access Programme (AAP)

Full Text

HPR1 Evaluating High-Cost Innovative Medicines: A Three-Year Analysis of Pricing Trends in France's Early Access Programme (AAP)

Abstract

Authors

H Sheppard M Orchard

Back to Volume 27, Supplemental Issue 12S

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now